The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Consolidation therapy for unresectable stage III EGFR-mutant NSCLC
Amin Nassar, MD, Yale Cancer Centre, New Haven, CT, outlines the rationale behind a retrospective analysis on consolidation therapy for unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC). The current standard of care for this patient subset is concurrent chemoradiation followed by consolidation durvalumab. Patients with EGFR-mutant NSCLC treated with consolidation durvalumab demonstrated a lower response rate compared EGFR-wild type tumours. The current treatment paradigm for this patient population is yet to be established. Dr Nassar shares that the retrospective analysis is necessary for addressing the unmet need of effective consolidation therapy for unresectable stage III EGFR-mutant NSCLC. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
